The use of quadrivalent influenza vaccines is a new standard in the prevention of this disease. They provide patients with the widest possible protection and are best suited to the current epidemiological situation. Thanks to the presence of 2 lines of influenza B virus in the vaccine, they eliminate the risk associated with the mismatch of influenza B virus in the vaccine.
Influenza is caused by three types of influenza virus: A, B and C. The A-type viruses (mainly A / H1N1 and A / H3N2) due to an antigenic jump may be the cause of the pandemic, whereas the B-type viruses (two Yamagata and Victoria lines), 2-4 years are the cause of the epidemic. The problem with the type B virus is that since 2000, both lines of this virus, Yamagata and Viktoria, have been circulating in the population at the same time, and their domination is changing. So predicting which line will dominate in the upcoming season is very difficult.
Four-standard standard
The answer to the influenza epidemiology that has changed in recent years, and in particular the simultaneous circulation in the population of both lines of influenza B type virus: Yamagata and Victoriasa, quadrivalent vaccines. It is the widest protection available and a new standard on the influenza vaccination market. It eliminates the risk of inappropriate selection of influenza B strain in the vaccine. Quadrivalent vaccines have at least the same high immune response for each of the three strains shared with the TIV vaccine and a higher immune response to strain B not included in the TIV vaccine. Quadrivalent vaccination instead Trinitarians can allow in 10 years in Europe an additional reduction of up to 1.6 million cases of influenza, 37.3 thousand. hospitalization and 14.8 thous. deaths. What is also important, the wider protection through the use of such vaccines will reduce the medical and economic consequences of influenza.
Recommendation of authorities
Quadrivalent influenza vaccines are available in the world and are increasingly used since 2013. They are commonly recommended by the most important public health institutions: WHOSAGE (Strategic Advisory Group of Experts), CDC (Advisory Committee on Immunization Practices, ACIP), ECDC (European Center for Disease Prevention and Control. In many countries in which quadrivalent vaccines are available, there are already local recommendations and reimbursement for patients from risk groups, eg Great Britain, Canada and Australia (children, seniors). In Poland, QIV vaccines are recommended by Experts of the National Program for Combating Influenza (www.opzg.pl).
Let us remember!
Each year, the world's influenza virus infects 5 to 10% of the adult population and between 20-30% of children. Influenza is a serious disease, and its complications can be fatal, influenza epidemics cause 250-500 thousand. deaths on a global scale and an average of 38.5 thousand. deaths in Europe alone. The most on the consequences of influenza are exposed to seniors and people suffering from chronic illness.
Sources:
